Skip to main content

Catalyst Calendar

Scope

Wed, Sep 9, 2026

1 updates
IRON
7:25 PM

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients DISC-3405 is the first monoclonal antibody targeting TMPRSS6 that has demonstrated phlebotomy reduction in

Presentation / Abstract • Phase 2Oral presentation Thu, Sep 10, 2026discmedicine.com

Wed, Sep 2, 2026

1 updates
IRON
8:00 AM

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company

discmedicine.com

Mon, Aug 31, 2026

1 updates
IRON
6:00 PM

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will

Presentation / Abstract • Phase 2SOHO poster presentation Wed, Sep 9, 2026, 6:25 PM CTdiscmedicine.com

Thu, Jul 30, 2026

1 updates